July 25, 2012 / 10:46 AM / 5 years ago

Regeneron boosts Eylea sales forecast - again

July 25 (Reuters) - Regeneron Pharmaceuticals Inc significantly boosted the 2012 sales forecast for its new eye drug Eylea for the third time this year as second-quarter sales of the sight-restoring medicine cruised past Wall Street's rising expectations.

The biotechnology company said on Wednesday that it expected full-year Eylea sales of $700 million to $750 million, up from an April forecast of $500 million to $550 million that was nearly double its previous projection.

Second-quarter sales of the eye drug, which since its November approval has been gaining market share from Roche Holding AG's Lucentis and off-label use of the cancer drug Avastin, were $194 million, up 57 percent from the previous quarter.

On Tuesday, Robert W. Baird analysts raised their Eylea sales forecast for the quarter to $155 million, ahead of Wall Street consensus expectations of about $143 million, and even that proved to be not aggressive enough. (Reporting by Bill Berkrot in New York; Editing by Lisa Von Ahn)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below